Ibuvit D3 2000 IU x 150 caps.
100% secure payments
zł50.44
Tax included
Description
Ibuvit D3 2000 IU x 150 caps.
Description
Composition and form: Each capsule contains 50 micrograms (2000 IU) of cholecalciferol (vitamin D3). Full list of excipients. Capsule, soft. Light yellow, oval soft capsules (shorter diameter approx. 6 mm) with a central seam, filled with a light yellow, oily liquid.
Indications: Prevention of vitamin D deficiency and conditions resulting from vitamin D deficiency (e.g. rickets, osteomalacia) in adults with normal body weight and children and adolescents with normal body weight aged 11 years and over. Supportive treatment of osteoporosis in adults. Prevention of vitamin D deficiency in women planning pregnancy, pregnant and breastfeeding,
in consultation with your doctor.
Indications: Prevention of vitamin D deficiency and conditions resulting from vitamin D deficiency (e.g. rickets, osteomalacia) in adults with normal body weight and children and adolescents with normal body weight aged 11 years and over. Supportive treatment of osteoporosis in adults. Prevention of vitamin D deficiency in women planning pregnancy, pregnant and breastfeeding,
in consultation with your doctor.
Storage and use
How to use: Use as directed by your doctor
Detailed instructions for use can be found in the leaflet included in the package.
Storage: Store at ambient temperature
Detailed instructions for use can be found in the leaflet included in the package.
Storage: Store at ambient temperature
Composition
Colecalciferol
Manufacturer
Zakłady Farmaceutyczne Polpharma S.A.
Manufacturer address
Zakłady Farmaceutyczne Polpharma S.A.,
street Pelplińska 19,
83-200 Starogard Gdański,
EN
Security Warning street Pelplińska 19,
83-200 Starogard Gdański,
EN
The total dose of vitamin D in patients consists of the vitamin D content of other medicinal products taken and foods rich in vitamin D consumed, as well as the vitamin produced by the body as a result of exposure to solar radiation. In Poland, sufficient exposure to sunlight is only possible in the period from May to
September and requires at least 15 minutes of exposure to the sun daily from 10:00 a.m. to 3:00 p.m., with forearms and lower legs uncovered,without using creams with UV filters. Vitamin D should be used with caution in patients with impaired renal function and its effect on calcium and phosphorus levels should be monitored. The risk of soft tissue calcification should be taken into account. In patients with renal impairment treated with Ibuvit D3, parameters of calcium and phosphate metabolism should be monitored. Caution is necessary in patients receiving treatment for cardiovascular disease. Vitamin D should be used with caution in patients with sarcoidosis due to the risk of increased conversion of vitamin D to its active form. Serum and urine calcium levels should be monitored in these patients. There are no significant indications for measuring 25(OH)D in the general population. Patients taking other medications, dietary supplements containing vitamin D (cholecalciferol), calcitriol
or other metabolites or vitamin D analogues should consult a doctor before taking Ibuvit D3 to select the appropriate dose. Patients with obesity (adults - BMI ≥ 30 kg/m2, children, adolescents - BMI > 90th percentile) require
twice the dose of vitamin D than recommended for peers of normal body weight. There is insufficient data on the effect of vitamin D administration on the formation of kidney stones, although such a risk is possible, especially in the case of additional calcium supplementation. The need for additional
must be considered individually calcium supplementation. Calcium levels in serum and urine should be monitored. In case of long-term use of vitamin D, especially daily doses significantly exceeding the recommended doses, calcium levels in serum and urine should be monitored and kidney function should be monitored by measuring creatinine levels. This is especially important in the case of
elderly patients and with simultaneous treatment with cardiac glycosides or thiazide diuretics that reduce urinary calcium excretion.
September and requires at least 15 minutes of exposure to the sun daily from 10:00 a.m. to 3:00 p.m., with forearms and lower legs uncovered,without using creams with UV filters. Vitamin D should be used with caution in patients with impaired renal function and its effect on calcium and phosphorus levels should be monitored. The risk of soft tissue calcification should be taken into account. In patients with renal impairment treated with Ibuvit D3, parameters of calcium and phosphate metabolism should be monitored. Caution is necessary in patients receiving treatment for cardiovascular disease. Vitamin D should be used with caution in patients with sarcoidosis due to the risk of increased conversion of vitamin D to its active form. Serum and urine calcium levels should be monitored in these patients. There are no significant indications for measuring 25(OH)D in the general population. Patients taking other medications, dietary supplements containing vitamin D (cholecalciferol), calcitriol
or other metabolites or vitamin D analogues should consult a doctor before taking Ibuvit D3 to select the appropriate dose. Patients with obesity (adults - BMI ≥ 30 kg/m2, children, adolescents - BMI > 90th percentile) require
twice the dose of vitamin D than recommended for peers of normal body weight. There is insufficient data on the effect of vitamin D administration on the formation of kidney stones, although such a risk is possible, especially in the case of additional calcium supplementation. The need for additional
must be considered individually calcium supplementation. Calcium levels in serum and urine should be monitored. In case of long-term use of vitamin D, especially daily doses significantly exceeding the recommended doses, calcium levels in serum and urine should be monitored and kidney function should be monitored by measuring creatinine levels. This is especially important in the case of
elderly patients and with simultaneous treatment with cardiac glycosides or thiazide diuretics that reduce urinary calcium excretion.
Product Details
Reviews
No customer reviews for the moment.